Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Jul 15;373(Pt 2):523–529. doi: 10.1042/BJ20030363

Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.

Jun Hyun Kim 1, Joo Hee Kim 1, Gun Eui Lee 1, Sang Woong Kim 1, In Kwon Chung 1
PMCID: PMC1223492  PMID: 12689331

Abstract

Telomere maintenance is essential for the continued proliferation of dividing cells, and is implicated in chromosome stability and cell immortalization. Telomerase activity allows cells to maintain their telomeric DNA and contributes to the indefinite replicative capacity of cancer cells. Telomerase is expressed in most cancer cells, but not in normal somatic cells, suggesting that telomerase is an attractive target for cancer chemotherapy. Here we screened a chemical library for inhibition of human telomerase, and identified 2,3,7-trichloro-5-nitroquinoxaline (TNQX) as a potent inhibitor. TNQX showed a potent inhibitory effect, with 50% inhibition at approximately 1.4 microM, and did not inhibit DNA and RNA polymerases, including retroviral reverse trancriptase. A series of enzyme kinetic experiments suggested that TNQX is a mixed-type non-competitive inhibitor, with an inhibitor-binding site distinct from the binding sites for the telomeric substrate (TS) primer and the dNTPs. Long-term cultivation of the MCF7 cell line with a drug concentration that did not cause acute cytotoxicity resulted in progressive telomere erosion followed by an increased incidence of chromosome abnormalities and induction of the senescence phenotype. The results presented here indicate that TNQX is a highly potent and selective anti-telomerase agent with good potential for further development as a promising anti-cancer agent.

Full Text

The Full Text of this article is available as a PDF (228.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama M., Horiguchi-Yamada J., Saito S., Hoshi Y., Yamada O., Mizoguchi H., Yamada H. Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer. 1999 Feb;35(2):309–315. doi: 10.1016/s0959-8049(98)00365-7. [DOI] [PubMed] [Google Scholar]
  2. Bearss D. J., Hurley L. H., Von Hoff D. D. Telomere maintenance mechanisms as a target for drug development. Oncogene. 2000 Dec 27;19(56):6632–6641. doi: 10.1038/sj.onc.1204092. [DOI] [PubMed] [Google Scholar]
  3. Blackburn E. H. Telomerases. Annu Rev Biochem. 1992;61:113–129. doi: 10.1146/annurev.bi.61.070192.000553. [DOI] [PubMed] [Google Scholar]
  4. Blackburn E. H. Telomere states and cell fates. Nature. 2000 Nov 2;408(6808):53–56. doi: 10.1038/35040500. [DOI] [PubMed] [Google Scholar]
  5. Blasco M. A., Lee H. W., Hande M. P., Samper E., Lansdorp P. M., DePinho R. A., Greider C. W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997 Oct 3;91(1):25–34. doi: 10.1016/s0092-8674(01)80006-4. [DOI] [PubMed] [Google Scholar]
  6. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998 Jan 16;279(5349):349–352. doi: 10.1126/science.279.5349.349. [DOI] [PubMed] [Google Scholar]
  7. Bryan T. M., Englezou A., Dalla-Pozza L., Dunham M. A., Reddel R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997 Nov;3(11):1271–1274. doi: 10.1038/nm1197-1271. [DOI] [PubMed] [Google Scholar]
  8. Bryan T. M., Englezou A., Gupta J., Bacchetti S., Reddel R. R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995 Sep 1;14(17):4240–4248. doi: 10.1002/j.1460-2075.1995.tb00098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burger A. M., Double J. A., Newell D. R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer. 1997 Apr;33(4):638–644. doi: 10.1016/s0959-8049(96)00521-7. [DOI] [PubMed] [Google Scholar]
  10. Counter C. M., Avilion A. A., LeFeuvre C. E., Stewart N. G., Greider C. W., Harley C. B., Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992 May;11(5):1921–1929. doi: 10.1002/j.1460-2075.1992.tb05245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., Niestroj C., Daiber C., Enenkel B., Guilliard B. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001 Dec 17;20(24):6958–6968. doi: 10.1093/emboj/20.24.6958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feng J., Funk W. D., Wang S. S., Weinrich S. L., Avilion A. A., Chiu C. P., Adams R. R., Chang E., Allsopp R. C., Yu J. The RNA component of human telomerase. Science. 1995 Sep 1;269(5228):1236–1241. doi: 10.1126/science.7544491. [DOI] [PubMed] [Google Scholar]
  13. Gasser S. M. A sense of the end. Science. 2000 May 26;288(5470):1377–1379. doi: 10.1126/science.288.5470.1377. [DOI] [PubMed] [Google Scholar]
  14. Gowan S. M., Heald R., Stevens M. F., Kelland L. R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol. 2001 Nov;60(5):981–988. doi: 10.1124/mol.60.5.981. [DOI] [PubMed] [Google Scholar]
  15. Gowan Sharon M., Harrison John R., Patterson Lisa, Valenti Melanie, Read Martin A., Neidle Stephen, Kelland Lloyd R. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol. 2002 May;61(5):1154–1162. doi: 10.1124/mol.61.5.1154. [DOI] [PubMed] [Google Scholar]
  16. Greider C. W. Telomere length regulation. Annu Rev Biochem. 1996;65:337–365. doi: 10.1146/annurev.bi.65.070196.002005. [DOI] [PubMed] [Google Scholar]
  17. Hackett Jennifer A., Greider Carol W. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002 Jan 21;21(4):619–626. doi: 10.1038/sj.onc.1205061. [DOI] [PubMed] [Google Scholar]
  18. Hahn W. C., Stewart S. A., Brooks M. W., York S. G., Eaton E., Kurachi A., Beijersbergen R. L., Knoll J. H., Meyerson M., Weinberg R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct;5(10):1164–1170. doi: 10.1038/13495. [DOI] [PubMed] [Google Scholar]
  19. Harley C. B., Futcher A. B., Greider C. W. Telomeres shorten during ageing of human fibroblasts. Nature. 1990 May 31;345(6274):458–460. doi: 10.1038/345458a0. [DOI] [PubMed] [Google Scholar]
  20. Harley C. B., Kim N. W., Prowse K. R., Weinrich S. L., Hirsch K. S., West M. D., Bacchetti S., Hirte H. W., Counter C. M., Greider C. W. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol. 1994;59:307–315. doi: 10.1101/sqb.1994.059.01.035. [DOI] [PubMed] [Google Scholar]
  21. Harley C. B. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991 Mar-Nov;256(2-6):271–282. doi: 10.1016/0921-8734(91)90018-7. [DOI] [PubMed] [Google Scholar]
  22. Hastie N. D., Dempster M., Dunlop M. G., Thompson A. M., Green D. K., Allshire R. C. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990 Aug 30;346(6287):866–868. doi: 10.1038/346866a0. [DOI] [PubMed] [Google Scholar]
  23. Hayakawa N., Nozawa K., Ogawa A., Kato N., Yoshida K., Akamatsu K. i., Tsuchiya M., Nagasaka A., Yoshida S. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry. 1999 Aug 31;38(35):11501–11507. doi: 10.1021/bi982829k. [DOI] [PubMed] [Google Scholar]
  24. Hiyama E., Gollahon L., Kataoka T., Kuroi K., Yokoyama T., Gazdar A. F., Hiyama K., Piatyszek M. A., Shay J. W. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996 Jan 17;88(2):116–122. doi: 10.1093/jnci/88.2.116. [DOI] [PubMed] [Google Scholar]
  25. Izbicka E., Wheelhouse R. T., Raymond E., Davidson K. K., Lawrence R. A., Sun D., Windle B. E., Hurley L. H., Von Hoff D. D. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 1999 Feb 1;59(3):639–644. [PubMed] [Google Scholar]
  26. Kang Mi Ran, Chung In Kwon. Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. Mol Pharmacol. 2002 Apr;61(4):879–884. doi: 10.1124/mol.61.4.879. [DOI] [PubMed] [Google Scholar]
  27. Kim Joo Hee, Kim Jun Hyun, Lee Gun Eui, Lee Jong Eun, Chung In Kwon. Potent inhibition of human telomerase by nitrostyrene derivatives. Mol Pharmacol. 2003 May;63(5):1117–1124. doi: 10.1124/mol.63.5.1117. [DOI] [PubMed] [Google Scholar]
  28. Kim Jun Hyun, Lee Gun Eui, Kim Jin Cheon, Lee Jun Ho, Chung In Kwon. A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. Mol Cells. 2002 Apr 30;13(2):228–236. [PubMed] [Google Scholar]
  29. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994 Dec 23;266(5193):2011–2015. doi: 10.1126/science.7605428. [DOI] [PubMed] [Google Scholar]
  30. Kim N. W., Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 1997 Jul 1;25(13):2595–2597. doi: 10.1093/nar/25.13.2595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kiyono T., Foster S. A., Koop J. I., McDougall J. K., Galloway D. A., Klingelhutz A. J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998 Nov 5;396(6706):84–88. doi: 10.1038/23962. [DOI] [PubMed] [Google Scholar]
  32. Kondo Y., Koga S., Komata T., Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene. 2000 Apr 27;19(18):2205–2211. doi: 10.1038/sj.onc.1203538. [DOI] [PubMed] [Google Scholar]
  33. Lingner J., Cooper J. P., Cech T. R. Telomerase and DNA end replication: no longer a lagging strand problem? Science. 1995 Sep 15;269(5230):1533–1534. doi: 10.1126/science.7545310. [DOI] [PubMed] [Google Scholar]
  34. Naasani I., Seimiya H., Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun. 1998 Aug 19;249(2):391–396. doi: 10.1006/bbrc.1998.9075. [DOI] [PubMed] [Google Scholar]
  35. Naasani I., Seimiya H., Yamori T., Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 1999 Aug 15;59(16):4004–4011. [PubMed] [Google Scholar]
  36. Pascolo Emanuelle, Wenz Christian, Lingner Joachim, Hauel Norbert, Priepke Henning, Kauffmann Iris, Garin-Chesa Pilar, Rettig Wolfgang J., Damm Klaus, Schnapp Andreas. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002 Feb 19;277(18):15566–15572. doi: 10.1074/jbc.M201266200. [DOI] [PubMed] [Google Scholar]
  37. Perry P. J., Read M. A., Davies R. T., Gowan S. M., Reszka A. P., Wood A. A., Kelland L. R., Neidle S. 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. J Med Chem. 1999 Jul 15;42(14):2679–2684. doi: 10.1021/jm990084q. [DOI] [PubMed] [Google Scholar]
  38. Pitts A. E., Corey D. R. Inhibition of human telomerase by 2'-O-methyl-RNA. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11549–11554. doi: 10.1073/pnas.95.20.11549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shay J. W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997 Apr;33(5):787–791. doi: 10.1016/S0959-8049(97)00062-2. [DOI] [PubMed] [Google Scholar]
  40. Strahl C., Blackburn E. H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996 Jan;16(1):53–65. doi: 10.1128/mcb.16.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998 Feb 26;8(5):279–282. doi: 10.1016/s0960-9822(98)70109-5. [DOI] [PubMed] [Google Scholar]
  42. White L. K., Wright W. E., Shay J. W. Telomerase inhibitors. Trends Biotechnol. 2001 Mar;19(3):114–120. doi: 10.1016/s0167-7799(00)01541-9. [DOI] [PubMed] [Google Scholar]
  43. Yokoyama Y., Takahashi Y., Shinohara A., Lian Z., Wan X., Niwa K., Tamaya T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 1998 Dec 1;58(23):5406–5410. [PubMed] [Google Scholar]
  44. Zhang X., Mar V., Zhou W., Harrington L., Robinson M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999 Sep 15;13(18):2388–2399. doi: 10.1101/gad.13.18.2388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. de Lange Titia. Protection of mammalian telomeres. Oncogene. 2002 Jan 21;21(4):532–540. doi: 10.1038/sj.onc.1205080. [DOI] [PubMed] [Google Scholar]
  46. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998 Feb 6;92(3):401–413. doi: 10.1016/s0092-8674(00)80932-0. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES